Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN-2Cat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| REGN-2Cat | EXPERIMENTAL | Part A and B |
| Freneslerbart | EXPERIMENTAL | Part A and B |
| Mevonlerbart | EXPERIMENTAL | Part A |
| Matching placebo | PLACEBO_COMPARATOR | Part A and B |
| Name | Type | Description |
|---|---|---|
| REGN-2Cat | DRUG | Administered per the protocol |
| Freneslerbart | DRUG | Administered per the protocol |
| Mevonlerbart | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Part A: adult participants aged 18 years and older. For part B: pediatric participants ≥8 years and \<18 years, and adult participants aged 18 years and older. 2. Positive SPT to cat allergen extract 3. Positive specific Immunoglobulin E (sIgE) tests for cat and Fel d 1 4...
REGN-2Cat is an investigational small molecule being developed for the treatment of allergic conjunctivitis, specifically in patients with cat allergy. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
REGN-2Cat targets Fel d 1, the major cat allergen, through monoclonal antibodies. The drug is designed to neutralize this allergen to reduce allergic responses in the eye, though the exact mechanism of action is not fully detailed in available information.
REGN-2Cat is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
REGN-2Cat is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 3 trial is actively recruiting participants.
REGN-2Cat is being studied in a Phase 3 clinical trial with the identifier NCT07675811. This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of Fel d 1 monoclonal antibodies in adult and pediatric participants with allergic conjunctivitis due to cat allergy, enrolling 570 participants in the United States.
REGN-2Cat is described as a small molecule, but the clinical trial for it uses Fel d 1 monoclonal antibodies. The drug may be referred to by this descriptive name in trial documentation, though the official drug name is REGN-2Cat.